Proven Process Medical Devices Announces Partnership with PathMaker Neurosystems

Wednesday, June 17, 2015 - 17:30

Companies Align to Develop Devices Based on Trans-Spinal Direct Current Stimulation (tsDCS) for Patients with Neuromotor Disorders

Mansfield, MA – June 18, 2015 – Proven Process Medical Devices Inc., a global leader in the design, development, validation, and manufacture of Class II and Class III medical devices, announced today that it has entered into a development agreement with PathMaker Neurosystems Inc. to develop and manufacture a first-in-class non-invasive device for treating patients with muscle tone disorders using trans-spinal direct current stimulation (tsDCS) technology.

Trans-spinal direct current stimulation is a novel modality for non-invasive neuromodulation that has recently emerged, driven by fundamental new understandings of spinal circuit biology. PathMaker expects its products to bring far-reaching changes in clinical practices for treating patients with neuromotor disorders. The Company’s tsDCS technology uses subthreshold direct current to directly modulate spinal circuits in a non-invasive manner using skin surface electrodes. The Company is currently developing a family of products based on tsDCS, and its first product, the MyoRegulator™, will open up a new therapeutic option for patients with muscle tone disorders.

Proven Process will refine the product design, building on PathMaker’s initial prototypes, and will create the controls needed for optimized operation and patient safety. Proven Process will apply its experience providing fully integrated contract manufacturing services for complex medical devices to build the new tsDCS products for clinical trials, regulatory submission and eventual commercial distribution.

“We are delighted to be working with Proven Process as we commercialize the first clinical products based on tsDCS,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker Neurosystems. “Proven Process’ expertise and reputation with device engineering and manufacture will facilitate our efforts as we move forward with our development plans for our tsDCS-based products.”


The MyoRegulator™ is an investigational device and is limited by United States law to investigational use only.

# # #

About PathMaker Neurosystems Inc.
PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology we are developing promises to open up entirely new methods of treating these patients.  For more information, please visit


For more information, contact:

Michael Kanis, Sale Engineer